Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA6 | P23280 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CASP2 | P42575 | 2/20 | 0.55 |
| ▸ | F13A1 | P00488 | 2/20 | 0.55 |
| ▸ | THPO | P40225 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756934 | 0.98 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL861102 | 0.98 | CASP2 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10110872 | 0.95 | CA12 (0.62) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10110868 | 0.93 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21214219 | 0.93 | CA12 (0.60) | CA12CA6CA7CA9CA14 | |
| SCHEMBL18827192 | 0.91 | CASP2 (0.62) | CA12CA6CA7CA9CA14 | |
| SCHEMBL989774 | 0.90 | — | — | |
| SCHEMBL861217 | 0.86 | CA12 (0.57) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19493346 | 0.85 | CYP2C19 (0.55) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25566473 | 0.85 | CYP2C19 (0.55) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672818-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210346424-A1 | NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-11-11 | — | — | US | disclosed |
| US-8143413-B2 | Polycationized phospholipid derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672818-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | NOS1, NOS2, NOS3 | CA12 3440/4885CA6 1791/4885CA7 1562/4885 |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | PHOSPHO1, PLTP, PTDSS2 | CA12 3209/4885CA6 2865/4885CA7 3427/4885 |
| US-20210346424-A1 | NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | CA12 3440/4885CA6 1791/4885CA7 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.